Daiichi Sankyo (OTCMKTS:DSNKY) Releases Earnings Results, Misses Estimates By $0.02 EPS

Daiichi Sankyo (OTCMKTS:DSNKY) issued its quarterly earnings results on Friday. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.02), Zacks reports. Daiichi Sankyo had a return on equity of 15.75% and a net margin of 12.32%. Daiichi Sankyo updated its FY 2026 guidance to 0.870-0.870 EPS.

Daiichi Sankyo Stock Down 11.5%

Shares of OTCMKTS DSNKY traded down $2.09 during mid-day trading on Friday, reaching $16.14. The company had a trading volume of 92,402 shares, compared to its average volume of 391,373. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.64 and a current ratio of 2.42. Daiichi Sankyo has a twelve month low of $14.98 and a twelve month high of $27.50. The stock’s 50 day moving average is $16.52 and its 200-day moving average is $17.74. The stock has a market capitalization of $30.07 billion, a PE ratio of 17.17, a price-to-earnings-growth ratio of 3.10 and a beta of -0.17.

Analysts Set New Price Targets

DSNKY has been the subject of a number of analyst reports. Zacks Research raised shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 5th. Jefferies Financial Group lowered shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.